Medical students present clinical educating faculty with feedback on their abilities as educators by means of nameless surveys on the finish of their clerkship rotation. Because faculty are ready of energy, students are hesitant to present candid feedback. Our goal was to decide if medical students had been prepared to present negative upward feedback to clinical faculty and describe how they conveyed their feedback. A qualitative evaluation of third year medical students’ open-ended feedback from evaluations of six clerkships was carried out utilizing politeness idea as a conceptual framework.
Students had been requested to describe how the clerkship enhanced their studying and the way it may very well be improved. Midway by means of the educational year, directions to present full names of faculty/residents was added. Overall, there have been considerably extra feedback on what labored effectively than recommendations for enchancment concerning faculty/residents. Instructing students to name-names elevated the speed of naming from 35% to 75% for what labored effectively and from 13% to 39% for recommendations for enchancment.
Hedging language was included in 61% of recommendations for enchancment, however solely 2% of what labored effectively. Students described the variability of their expertise, used passive language and certified negative experiences with constructive ones. Medical students could use linguistic methods, equivalent to impersonalizing and hedging, to mitigate the affect of negative upward feedback. Working in the direction of a tradition that helps upward feedback would enable students to really feel extra comfy providing candid feedback about their expertise.
Medical students’ and faculty expertise in studying and educating household medication in Vellore
The first household medication coaching programme for medical students in India started at Christian Medical College (CMC), Vellore in 2005 as a two-week programme. Currently, it consists of two obligatory and one elective programme together with one to two weeks through the internship. In this examine, the authors examined the affect of the obligatory programmes in household medication by means of the feedback of medical students and the faculty expertise.
The purpose of the authors was to study the affect on medical students primarily based on their feedback and the expertise of faculty in educating household medication. This paper studies a retrospective analysis primarily based on the feedback of third-year medical students after their obligatory programmes in 2018. The authors collected students’ feedback utilizing questionnaires and recorded the faculty expertise by means of a focus-group dialogue (FGD) and in-depth interview.
Overall attendance of students was 50-60%. About 75% of students who crammed within the questionnaire felt the programme to be related to their future function as ‘Physicians of First Contact’. Faculty felt challenged to stability their function as lecturers as well as to their clinical duties. However, introducing household medication rules within the medical curriculum was sensed by the faculty to equip students to handle frequent clinical circumstances successfully. In conclusion students’ understanding of the distinctive standing of household medication to accommodate sufferers of all ages and issues inside a single umbrella health-care system was effectively discerned by the authors on this examine.
Protecting the Well-Being of Medical Residents and Faculty Physicians During the COVID-19 Pandemic: Making the Case for Accessible, Comprehensive Wellness Resources
Accounts of frontline well being care employees experiencing misery within the midst of the COVID-19 pandemic spotlight the necessity for accessible psychological help for them. Prior to the pandemic, medical residents and physicians typically skilled problem receiving counseling due to issues about confidentiality, stigma, value, time, and reportability to licensure/credentialing our bodies. Since 2004, the OHSU Resident and Faculty Wellness Program (RFWP) crew has sought to cut back these boundaries by providing on-site free, confidential, particular person counseling and medicine administration.
Utilization of this program is excessive with over 500 physicians a year in search of care; 38% of all OHSU residents/fellows and 7% of all faculty eligible for our providers participated in 2019-20. In the current essay, we describe how our mannequin of look after trainees and faculty was a key wellness useful resource throughout COVID-19. Similar to different accounts of decrease help-seeking by well being professionals initially through the pandemic, we skilled a slight downturn in utilization charges through the preliminary weeks of when the pandemic struck our space, however shortly returned to regular and exceeded prior ranges.
All appointments shifted to telehealth visits and a lot of physicians expressed gratitude for the chance to discuss by means of issues and strengthen coping. Plenty of physicians requested medicine consultations to handle extreme insomnia, nervousness, and despair. We hope that being current in our physicians’ lives when they’re uncovered to COVID-related stress or trauma will maintain them protected, assist them deal with tough experiences and losses, and finally facilitate each restoration and post-traumatic progress.
Medical Educators’ Perceptions of Research Culture in a Faculty of Health Sciences: A South African Study
Phenomenon: In South Africa, as with many different growing international locations, a name has been made for establishments of upper studying to take part in additional analysis and set the tempo for societal transformation. At the Faculty of Health Sciences (FoHS), University of the Free State (UFS), quite a few strategic efforts are targeted on supporting and stimulating analysis. An important prerequisite for the success of those important efforts is to concentrate on the analysis tradition throughout the tutorial schools.
A peculiarity of medical schools in South Africa is that medical schools are in partnership with the federal government by means of the educational coaching hospitals; therefore, employees appointment happens by means of a joint construction with each the provincial Department of Health and the National Health Laboratory Services. So far, no recognized examine has investigated analysis tradition on this context (joint employees appointment). Approach: This examine included parts of case examine analysis and improvement-oriented analysis. We distributed to 242 educators a structured questionnaire to receive perceptions of points of analysis, analysis processes, and present analysis tradition within the FoHS, UFS. Suggestions on how to enhance the analysis tradition additionally had been obtained.
The structured questionnaire was self-administered, consisted of closed and open-ended questions grouped into 5 fundamental sections, and was distributed electronically and manually (laborious copy) to individuals. Findings: One-hundred-eleven questionnaires had been returned (46% response price). Motivation to do analysis diversified by college and included profession development (77%, School of Allied Health Professions); change the state of affairs (80%, Academic help); develop particular person skillset (67%, School of Nursing) and enhance affected person care (62%, School of Medicine).
Perceived elements affecting analysis tradition included restricted funding and allotted time for analysis, minimal management help for analysis, and absence of research-related help buildings in addition to minimal teamwork/collaboration. Frustration was essentially the most reported (negative) emotion (25%). Participants prompt that encouraging teamwork amongst employees, lowering workload to enable time for analysis, establishing a mentorship program, providing coaching on poor abilities, and extra help from management would enhance analysis tradition. Insights:
This current examine reveals a few of the elements that affect negatively on analysis, analysis tradition, and productiveness in a medical faculty in a resource-limited setting. While the advantages of joint employees appointment can’t be overemphasized, our findings spotlight that the advanced interaction between employers/stakeholders end in poorly executed joint appointment scheme/fashions (i.e., aggressive method) and creates quite a few challenges that negatively affect analysis productiveness and analysis tradition.
Exosome Component 9 Protein |
|||
| abx262123-5mg | Abbexa | 5 mg | EUR 225 |
Exosome Component 8 (EXOSC8) Antibody |
|||
| 20-abx318649 | Abbexa |
|
|
Exosome Component 3 (EXOSC3) Antibody |
|||
| 20-abx312069 | Abbexa |
|
|
Exosome Component 1 (EXOSC1) Antibody |
|||
| 20-abx301763 | Abbexa |
|
|
Exosome Component 5 (EXOSC5) Antibody |
|||
| 20-abx302857 | Abbexa |
|
|
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx034983-400ul | Abbexa | 400 ul | EUR 627.6 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx034983-80l | Abbexa | 80 µl | EUR 343.2 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| 20-abx176346 | Abbexa |
|
|
Exosome Component 2 (EXOSC2) Antibody |
|||
| 20-abx172308 | Abbexa |
|
|
Exosome Component 7 (EXOSC7) Antibody |
|||
| 20-abx124556 | Abbexa |
|
|
Exosome Component 4 (EXOSC4) Antibody |
|||
| 20-abx124664 | Abbexa |
|
|
Exosome Component 1 (EXOSC1) Antibody |
|||
| 20-abx125829 | Abbexa |
|
|
Exosome Component 2 (EXOSC2) Antibody |
|||
| 20-abx125830 | Abbexa |
|
|
Exosome Component 3 (EXOSC3) Antibody |
|||
| 20-abx125831 | Abbexa |
|
|
Exosome Component 1 (EXOSC1) Antibody |
|||
| abx232898-100ug | Abbexa | 100 ug | EUR 577.2 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx232901-100ug | Abbexa | 100 ug | EUR 577.2 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx232902-100ug | Abbexa | 100 ug | EUR 661.2 |
Exosome Component 3 (EXOSC3) Antibody |
|||
| abx232903-100ug | Abbexa | 100 ug | EUR 577.2 |
Exosome Component 4 (EXOSC4) Antibody |
|||
| abx232904-100ug | Abbexa | 100 ug | EUR 577.2 |
Exosome Component 5 (EXOSC5) Antibody |
|||
| abx232905-100ug | Abbexa | 100 ug | EUR 610.8 |
Exosome Component 7 (EXOSC7) Antibody |
|||
| abx232906-100ug | Abbexa | 100 ug | EUR 661.2 |
Exosome Component 8 (EXOSC8) Antibody |
|||
| abx232907-100ug | Abbexa | 100 ug | EUR 577.2 |
Exosome Component 1 (EXOSC1) Antibody |
|||
| 20-abx112409 | Abbexa |
|
|
Exosome Component 2 (EXOSC2) Antibody |
|||
| 20-abx112411 | Abbexa |
|
|
Exosome Component 3 (EXOSC3) Antibody |
|||
| 20-abx112412 | Abbexa |
|
|
Exosome Component 4 (EXOSC4) Antibody |
|||
| 20-abx112413 | Abbexa |
|
|
Exosome Component 5 (EXOSC5) Antibody |
|||
| 20-abx112414 | Abbexa |
|
|
Exosome Component 8 (EXOSC8) Antibody |
|||
| 20-abx112415 | Abbexa |
|
|
Exosome Component 8 (EXOSC8) Antibody |
|||
| 20-abx003377 | Abbexa |
|
|
Exosome Component 2 (EXOSC2) Antibody |
|||
| 20-abx003412 | Abbexa |
|
|
Exosome Component 1 (EXOSC1) Antibody |
|||
| abx030303-400ul | Abbexa | 400 ul | EUR 627.6 |
Exosome Component 1 (EXOSC1) Antibody |
|||
| abx030303-80l | Abbexa | 80 µl | EUR 343.2 |
Exosome Component 8 (EXOSC8) Antibody |
|||
| abx031706-400ul | Abbexa | 400 ul | EUR 627.6 |
Exosome Component 8 (EXOSC8) Antibody |
|||
| abx031706-80l | Abbexa | 80 µl | EUR 343.2 |
Exosome Component 4 (EXOSC4) Antibody |
|||
| abx029390-400ul | Abbexa | 400 ul | EUR 627.6 |
Exosome Component 4 (EXOSC4) Antibody |
|||
| abx029390-80l | Abbexa | 80 µl | EUR 343.2 |
Exosome Component 8 (EXOSC8) Antibody |
|||
| abx003377-100l | Abbexa | 100 µl | EUR 400 |
Exosome Component 8 (EXOSC8) Antibody |
|||
| abx003377-20l | Abbexa | 20 µl | EUR 175 |
Exosome Component 8 (EXOSC8) Antibody |
|||
| abx003377-50l | Abbexa | 50 µl | EUR 275 |
Exosome Component 1 (EXOSC1) Antibody |
|||
| abx301763-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 1 (EXOSC1) Antibody |
|||
| abx301763-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 1 (EXOSC1) Antibody |
|||
| abx301763-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 5 (EXOSC5) Antibody |
|||
| abx302857-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 5 (EXOSC5) Antibody |
|||
| abx302857-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 5 (EXOSC5) Antibody |
|||
| abx302857-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 1 (EXOSC1) Antibody |
|||
| abx125829-100l | Abbexa | 100 µl | EUR 175 |
Exosome Component 1 (EXOSC1) Antibody |
|||
| abx125829-1ml | Abbexa | 1 ml | EUR 400 |
Exosome Component 1 (EXOSC1) Antibody |
|||
| abx125829-200l | Abbexa | 200 µl | EUR 275 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx125830-100l | Abbexa | 100 µl | EUR 175 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx125830-1ml | Abbexa | 1 ml | EUR 400 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx125830-200l | Abbexa | 200 µl | EUR 275 |
Exosome Component 3 (EXOSC3) Antibody |
|||
| abx125831-100l | Abbexa | 100 µl | EUR 175 |
Exosome Component 3 (EXOSC3) Antibody |
|||
| abx125831-1ml | Abbexa | 1 ml | EUR 400 |
Exosome Component 3 (EXOSC3) Antibody |
|||
| abx125831-200l | Abbexa | 200 µl | EUR 275 |
Exosome Component 1 (EXOSC1) Antibody |
|||
| abx112409-100l | Abbexa | 100 µl | EUR 612.5 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx112411-100l | Abbexa | 100 µl | EUR 612.5 |
Exosome Component 3 (EXOSC3) Antibody |
|||
| abx112412-100l | Abbexa | 100 µl | EUR 612.5 |
Exosome Component 4 (EXOSC4) Antibody |
|||
| abx112413-100l | Abbexa | 100 µl | EUR 612.5 |
Exosome Component 5 (EXOSC5) Antibody |
|||
| abx112414-100l | Abbexa | 100 µl | EUR 612.5 |
Exosome Component 8 (EXOSC8) Antibody |
|||
| abx112415-100l | Abbexa | 100 µl | EUR 612.5 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx034983-100g | Abbexa | 100 µg | EUR 281.25 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx176346-1096tests | Abbexa | 10 × 96 tests | EUR 750 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx176346-596tests | Abbexa | 5 × 96 tests | EUR 337.5 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx176346-96tests | Abbexa | 96 tests | EUR 275 |
Exosome Component 1 (EXOSC1) Antibody |
|||
| abx232898-100g | Abbexa | 100 µg | EUR 350 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx232901-100g | Abbexa | 100 µg | EUR 350 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx232902-100g | Abbexa | 100 µg | EUR 350 |
Exosome Component 3 (EXOSC3) Antibody |
|||
| abx232903-100g | Abbexa | 100 µg | EUR 350 |
Exosome Component 4 (EXOSC4) Antibody |
|||
| abx232904-100g | Abbexa | 100 µg | EUR 350 |
Exosome Component 5 (EXOSC5) Antibody |
|||
| abx232905-100g | Abbexa | 100 µg | EUR 350 |
Exosome Component 7 (EXOSC7) Antibody |
|||
| abx232906-100g | Abbexa | 100 µg | EUR 350 |
Exosome Component 8 (EXOSC8) Antibody |
|||
| abx232907-100g | Abbexa | 100 µg | EUR 350 |
Exosome Component 4 (EXOSC4) Antibody |
|||
| abx029390-400l | Abbexa | 400 µl | EUR 518.75 |
Exosome Component 3 (EXOSC3) Antibody |
|||
| abx312069-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 3 (EXOSC3) Antibody |
|||
| abx312069-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 3 (EXOSC3) Antibody |
|||
| abx312069-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 1 (EXOSC1) Antibody |
|||
| abx030303-400l | Abbexa | 400 µl | EUR 518.75 |
Exosome Component 8 (EXOSC8) Antibody |
|||
| abx031706-400l | Abbexa | 400 µl | EUR 518.75 |
Exosome Component 7 (EXOSC7) Antibody |
|||
| abx124556-100l | Abbexa | 100 µl | EUR 175 |
Exosome Component 7 (EXOSC7) Antibody |
|||
| abx124556-1ml | Abbexa | 1 ml | EUR 400 |
Exosome Component 7 (EXOSC7) Antibody |
|||
| abx124556-200l | Abbexa | 200 µl | EUR 275 |
Exosome Component 4 (EXOSC4) Antibody |
|||
| abx124664-100l | Abbexa | 100 µl | EUR 175 |
Exosome Component 4 (EXOSC4) Antibody |
|||
| abx124664-1ml | Abbexa | 1 ml | EUR 400 |
Exosome Component 4 (EXOSC4) Antibody |
|||
| abx124664-200l | Abbexa | 200 µl | EUR 275 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx172308-1ml | Abbexa | 1 ml | EUR 787.5 |
Exosome Component 8 (EXOSC8) Antibody |
|||
| abx318649-100l | Abbexa | 100 µl | EUR 250 |
Exosome Component 8 (EXOSC8) Antibody |
|||
| abx318649-50l | Abbexa | 50 µl | EUR 162.5 |
Exosome Component 10 (EXOSC10) Antibody |
|||
| 20-abx334343 | Abbexa |
|
|
Exosome Component 10 (EXOSC10) Antibody |
|||
| abx232899-100ug | Abbexa | 100 ug | EUR 661.2 |
Exosome Component 10 (EXOSC10) Antibody |
|||
| abx232900-100ug | Abbexa | 100 ug | EUR 610.8 |
Exosome Component 10 (EXOSC10) Antibody |
|||
| 20-abx112410 | Abbexa |
|
|
Exosome Component 10 (EXOSC10) Antibody |
|||
| abx112410-100l | Abbexa | 100 µl | EUR 612.5 |
Exosome Component 10 (EXOSC10) Antibody |
|||
| abx232899-100g | Abbexa | 100 µg | EUR 350 |
Exosome Component 10 (EXOSC10) Antibody |
|||
| abx232900-100g | Abbexa | 100 µg | EUR 350 |
Exosome Component 10 (EXOSC10) Antibody |
|||
| abx334343-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 10 (EXOSC10) Antibody |
|||
| abx334343-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 10 (EXOSC10) Antibody |
|||
| abx334343-50g | Abbexa | 50 µg | EUR 250 |
Recombinant Human Exosome Component 9 |
|||
| 7-05902 | CHI Scientific | 2µg | Ask for price |
Recombinant Human Exosome Component 9 |
|||
| 7-05903 | CHI Scientific | 10µg | Ask for price |
Recombinant Human Exosome Component 9 |
|||
| 7-05904 | CHI Scientific | 1mg | Ask for price |
Exosome Component 9 Human Recombinant |
|||
| rAP-3266 | Angio Proteomie | Inquiry | Ask for price |
Exosome Component 5 (EXOSC5) Antibody (HRP) |
|||
| 20-abx311411 | Abbexa |
|
|
Exosome Component 3 (EXOSC3) Antibody (HRP) |
|||
| 20-abx312070 | Abbexa |
|
|
Exosome Component 1 (EXOSC1) Antibody (HRP) |
|||
| 20-abx312486 | Abbexa |
|
|
Exosome Component 8 (EXOSC8) Antibody (HRP) |
|||
| 20-abx310194 | Abbexa |
|
|
Exosome Component 8 (EXOSC8) Antibody (HRP) |
|||
| abx310194-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 8 (EXOSC8) Antibody (HRP) |
|||
| abx310194-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 8 (EXOSC8) Antibody (HRP) |
|||
| abx310194-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 5 (EXOSC5) Antibody (HRP) |
|||
| abx311411-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 5 (EXOSC5) Antibody (HRP) |
|||
| abx311411-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 5 (EXOSC5) Antibody (HRP) |
|||
| abx311411-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 3 (EXOSC3) Antibody (HRP) |
|||
| abx312070-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 3 (EXOSC3) Antibody (HRP) |
|||
| abx312070-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 3 (EXOSC3) Antibody (HRP) |
|||
| abx312070-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 1 (EXOSC1) Antibody (HRP) |
|||
| abx312486-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 1 (EXOSC1) Antibody (HRP) |
|||
| abx312486-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 1 (EXOSC1) Antibody (HRP) |
|||
| abx312486-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 5 (EXOSC5) Antibody (FITC) |
|||
| 20-abx311412 | Abbexa |
|
|
Exosome Component 3 (EXOSC3) Antibody (FITC) |
|||
| 20-abx312071 | Abbexa |
|
|
Exosome Component 1 (EXOSC1) Antibody (FITC) |
|||
| 20-abx312487 | Abbexa |
|
|
Exosome Component 10 (EXOSC10) Antibody (HRP) |
|||
| 20-abx335640 | Abbexa |
|
|
Exosome Component 8 (EXOSC8) Antibody (FITC) |
|||
| 20-abx310195 | Abbexa |
|
|
Exosome Component 8 (EXOSC8) Antibody (FITC) |
|||
| abx310195-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 8 (EXOSC8) Antibody (FITC) |
|||
| abx310195-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 8 (EXOSC8) Antibody (FITC) |
|||
| abx310195-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 5 (EXOSC5) Antibody (FITC) |
|||
| abx311412-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 5 (EXOSC5) Antibody (FITC) |
|||
| abx311412-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 5 (EXOSC5) Antibody (FITC) |
|||
| abx311412-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 3 (EXOSC3) Antibody (FITC) |
|||
| abx312071-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 3 (EXOSC3) Antibody (FITC) |
|||
| abx312071-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 3 (EXOSC3) Antibody (FITC) |
|||
| abx312071-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 1 (EXOSC1) Antibody (FITC) |
|||
| abx312487-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 1 (EXOSC1) Antibody (FITC) |
|||
| abx312487-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 1 (EXOSC1) Antibody (FITC) |
|||
| abx312487-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 10 (EXOSC10) Antibody (HRP) |
|||
| abx335640-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 10 (EXOSC10) Antibody (HRP) |
|||
| abx335640-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 10 (EXOSC10) Antibody (HRP) |
|||
| abx335640-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 10 (EXOSC10) Antibody (FITC) |
|||
| 20-abx335641 | Abbexa |
|
|
Exosome Component 10 (EXOSC10) Antibody (FITC) |
|||
| abx335641-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 10 (EXOSC10) Antibody (FITC) |
|||
| abx335641-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 10 (EXOSC10) Antibody (FITC) |
|||
| abx335641-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 5 (EXOSC5) Antibody (Biotin) |
|||
| 20-abx311413 | Abbexa |
|
|
Exosome Component 3 (EXOSC3) Antibody (Biotin) |
|||
| 20-abx312072 | Abbexa |
|
|
Exosome Component 1 (EXOSC1) Antibody (Biotin) |
|||
| 20-abx312488 | Abbexa |
|
|
Exosome Component 8 (EXOSC8) Antibody (Biotin) |
|||
| 20-abx310196 | Abbexa |
|
|
Exosome Component 8 (EXOSC8) Antibody (Biotin) |
|||
| abx310196-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 8 (EXOSC8) Antibody (Biotin) |
|||
| abx310196-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 8 (EXOSC8) Antibody (Biotin) |
|||
| abx310196-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 5 (EXOSC5) Antibody (Biotin) |
|||
| abx311413-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 5 (EXOSC5) Antibody (Biotin) |
|||
| abx311413-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 5 (EXOSC5) Antibody (Biotin) |
|||
| abx311413-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 3 (EXOSC3) Antibody (Biotin) |
|||
| abx312072-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 3 (EXOSC3) Antibody (Biotin) |
|||
| abx312072-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 3 (EXOSC3) Antibody (Biotin) |
|||
| abx312072-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 1 (EXOSC1) Antibody (Biotin) |
|||
| abx312488-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 1 (EXOSC1) Antibody (Biotin) |
|||
| abx312488-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 1 (EXOSC1) Antibody (Biotin) |
|||
| abx312488-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 10 (EXOSC10) Antibody (Biotin) |
|||
| 20-abx335642 | Abbexa |
|
|
Exosome Component 10 (EXOSC10) Antibody (Biotin) |
|||
| abx335642-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 10 (EXOSC10) Antibody (Biotin) |
|||
| abx335642-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 10 (EXOSC10) Antibody (Biotin) |
|||
| abx335642-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 2 (EXOSC2) Polyclonal Antibody |
|||
| CAU30293-100ul | Biomatik Corporation | 100ul | EUR 235.2 |
Exosome Component 2 (EXOSC2) Polyclonal Antibody |
|||
| CAU30293-200ul | Biomatik Corporation | 200ul | EUR 294 |
Rat Exosome Component 9 (EXOSC9) ELISA Kit |
|||
| abx522550-96tests | Abbexa | 96 tests | EUR 687.5 |
Human Exosome Component 9 (EXOSC9) ELISA Kit |
|||
| abx387227-96tests | Abbexa | 96 tests | EUR 1093.2 |
Human Exosome Component 9(EXOSC9) ELISA kit |
|||
| YLA4369HU-48T | Shanghai YL Biotech | 48T | Ask for price |
Recommendations prompt herein could be applied by the FoHS and different medical schools in comparable contexts to enhance analysis productiveness and foster an enabling analysis tradition.